The Role of Phosphodiesterase 9a Inhibitors in Heart Failure

Authors

Saam Foroshani, Medicine, New York Medical College, Valhalla, NY, USA.
Avrohom Karp, Medicine, New York Medical College, Valhalla, NY, USA.
Wilbert S. Aronow, Departments of Cardiology and Medicine Westchester Medical Center, New York Medical College, Valhalla, NY, USA.Follow
Gregg M. Lanier, Departments of Cardiology and Medicine Westchester Medical Center, New York Medical College, Valhalla, NY, USA.Follow

Author Type(s)

Faculty, Student

DOI

10.1080/13543784.2024.2349813

Journal Title

Expert Opinion on Investigational Drugs

First Page

543

Last Page

547

Document Type

Article

Publication Date

6-1-2024

Department

Medicine

Abstract

INTRODUCTION: There are currently limited effective treatments available to improve lusitropy in patients suffering from heart failure with preserved ejection fraction. The role of PDE9A in diastolic dysfunction has been well-studied over recent years, with a special focus on its association with myocardial hypertrophy. Recent insights into PDE9A inhibition have brought to light the potential for reversal of cardiac remodeling, with multiple studies showing promising results in preclinical data. AREAS COVERED: This expert opinion provides an overview of the role of PDE9A in diastolic heart dysfunction along with the efficacy of PDE9A inhibitors in laboratory models of heart failure with preserved ejection fraction. EXPERT OPINION: The available data on PDE9A inhibition in preclinical studies suggest that there is potential for reversal of diastolic dysfunction and myocardial hypertrophy, however, conflicting data suggests that further studies are required before progressing to clinical trials.

Recommended Citation

Foroshani, S., Karp, A., Aronow, W. S., & Lanier, G. M. (2024). The Role of Phosphodiesterase 9a Inhibitors in Heart Failure. Expert Opinion on Investigational Drugs, 33 (6), 543-547. https://doi.org/10.1080/13543784.2024.2349813